Galectin Therapeutics (NASDAQ:GALT - Get Free Report) is projected to announce its Q4 2024 earnings results before the market opens on Friday, April 4th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter.
Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last issued its quarterly earnings data on Friday, April 4th. The company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.03). On average, analysts expect Galectin Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Galectin Therapeutics Stock Down 19.7 %
Shares of GALT traded down $0.30 during midday trading on Monday, reaching $1.22. 435,475 shares of the stock were exchanged, compared to its average volume of 325,835. The stock's 50 day simple moving average is $1.45 and its 200 day simple moving average is $1.97. The company has a market cap of $76.57 million, a P/E ratio of -1.67 and a beta of 0.69. Galectin Therapeutics has a twelve month low of $0.73 and a twelve month high of $4.27.
Analysts Set New Price Targets
GALT has been the subject of several analyst reports. HC Wainwright reiterated a "neutral" rating on shares of Galectin Therapeutics in a research note on Friday, December 27th. StockNews.com cut Galectin Therapeutics from a "hold" rating to a "sell" rating in a research note on Monday, December 30th.
Get Our Latest Stock Analysis on Galectin Therapeutics
Institutional Inflows and Outflows
An institutional investor recently raised its position in Galectin Therapeutics stock. Bank of America Corp DE grew its holdings in shares of Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) by 101.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 38,358 shares of the company's stock after acquiring an additional 19,316 shares during the quarter. Bank of America Corp DE owned 0.06% of Galectin Therapeutics worth $49,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 11.68% of the company's stock.
Galectin Therapeutics Company Profile
(
Get Free Report)
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.
See Also
Before you consider Galectin Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Galectin Therapeutics wasn't on the list.
While Galectin Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
